Dose Dense Chemotherapy Regimen Improves Survival In Breast Cancer
Novartis Begins Study Of Femara And Zometa In Postmenopausal Early Breast Cancer
Arimidex Continues To Show Improvement Over Tamoxifen
Iressa May Benefit Some Breast Cancer, Studies Find
Gleevec Improves Survival Of CML In Accelerated Phase
Phase II Study Tests Chemo Plus Mylotarg For AML
“Proof Of Concept” Shown In Early Trial Of PKC-412
Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis
Clinical Trials Approved By NCI During November Are Listed
Trending Stories
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures - In weekly vigils, current and former NIH staff grieve the impact of Trump cuts
The Saturday gatherings at NIH’s Metro station are part graveside service, part street theater - She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research
- Scaling excellence: How City of Hope is transforming cancer care delivery
- First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI
